×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HEPA – hepion pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HEPA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
08:00 am
hepa
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
Low
Report
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
9/4
09:33 am
hepa
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger [Yahoo! Finance]
Medium
Report
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger [Yahoo! Finance]
9/4
09:25 am
hepa
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Medium
Report
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
05:01 pm
hepa
Form 8-K Hepion Pharmaceuticals, For: Nov 20
Medium
Report
Form 8-K Hepion Pharmaceuticals, For: Nov 20
11/21
05:01 pm
hepa
Form 425 Hepion Pharmaceuticals, Filed by: Hepion Pharmaceuticals, Inc.
Medium
Report
Form 425 Hepion Pharmaceuticals, Filed by: Hepion Pharmaceuticals, Inc.
11/14
04:53 pm
hepa
Form 10-Q Hepion Pharmaceuticals, For: Sep 30
Medium
Report
Form 10-Q Hepion Pharmaceuticals, For: Sep 30
11/14
04:09 pm
hepa
Form SC 13G/A Hepion Pharmaceuticals, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G/A Hepion Pharmaceuticals, Filed by: ARMISTICE CAPITAL, LLC
9/5
06:37 am
hepa
Form 425 Hepion Pharmaceuticals, Filed by: Hepion Pharmaceuticals, Inc.
Medium
Report
Form 425 Hepion Pharmaceuticals, Filed by: Hepion Pharmaceuticals, Inc.
9/5
06:29 am
hepa
Form 8-K Hepion Pharmaceuticals, For: Sep 03
Medium
Report
Form 8-K Hepion Pharmaceuticals, For: Sep 03
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/16
Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases
43.2%
11/20 Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease 38.4%
1/28 Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study 15.3%
4/23 ContraVir Pharmaceuticals Inc (NYSE: HEPA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.7%
11/26 Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs [Seeking Alpha] 12.1%
4/30 ContraVir Pharmaceuticals Inc (NYSE: HEPA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 12.0%
3/27 Form 424B5 Hepion Pharmaceuticals, 8.8%
11/7 Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019 8.3%
12/3 Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference 8.1%
1/6 Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs 7.4%
11/20 Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease 38.4%
1/28 Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study 15.3%
4/23 ContraVir Pharmaceuticals Inc (NYSE: HEPA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.7%
11/26 Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs [Seeking Alpha] 12.1%
4/30 ContraVir Pharmaceuticals Inc (NYSE: HEPA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 12.0%
3/27 Form 424B5 Hepion Pharmaceuticals, 8.8%
11/7 Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019 8.3%
12/3 Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference 8.1%
1/6 Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs 7.4%
TOP News Decliners
3/12
Form 8-K Hepion Pharmaceuticals, For: Mar 12
-25.1%
7/29 Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH -20.6%
8/14 Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 -13.4%
11/21 Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment [MarketWatch] -11.5%
11/9 ContraVir Pharmaceuticals Inc (NYSE: HEPA) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.3%
1/6 Form 8-K Hepion Pharmaceuticals, For: Jan 06 -6.0%
4/17 Form 8-K Hepion Pharmaceuticals, For: Apr 13 -6.0%
12/10 Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 -5.9%
2/12 Form 8-K Hepion Pharmaceuticals, For: Feb 12 -5.5%
2/20 Form 8-K Hepion Pharmaceuticals, For: Feb 19 -5.4%
7/29 Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH -20.6%
8/14 Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 -13.4%
11/21 Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment [MarketWatch] -11.5%
11/9 ContraVir Pharmaceuticals Inc (NYSE: HEPA) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.3%
1/6 Form 8-K Hepion Pharmaceuticals, For: Jan 06 -6.0%
4/17 Form 8-K Hepion Pharmaceuticals, For: Apr 13 -6.0%
12/10 Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 -5.9%
2/12 Form 8-K Hepion Pharmaceuticals, For: Feb 12 -5.5%
2/20 Form 8-K Hepion Pharmaceuticals, For: Feb 19 -5.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: